2023年6月27日

RLS已成为分销商苏菲的放射性药物的药剂量。苏菲,美国生产商宠物放射性药物,使得RLS(放射性同位素生命科学),第三大核医学药店网络,一个官方经销商的药剂量。通过该交易,苏菲能够扩展到新的市场,与RLS准备和分发所有病人剂量苏菲选择客户,包括医院、教学机构,和医生。苏菲生产配合,Pylarify Neuraceq其他放射性药物的解决方案用于每年超过400000患者的护理,拥有知识产权的成纤维细胞激活蛋白抑制剂(FAPI),已被用于照顾大约28种不同癌症。充分保证和支持的公司你可以信任!今天打电话或点击免费报价!www.Centrifugestore.com 800-457-7576也促进医药研发和合同制造业务合作伙伴和自己的专利药物开发,并且有开展卓越中心,于2022年5月全球生产和分发多个治疗放射性药物提供者。RLS是一个联合委员会认可的31 radiopharmacies网络从通用电气医疗集团在2020年获得的,分布在18个州。其投资组合由锝99 m (tc - 99 m)和non-technetium产品,氯化tl - 201和i - 123 ioflupane,以及冷包和配件。这是唯一认可radiopharmacy网络,运行一年365天24/7。 “Compounding and delivering thousands of patient doses daily, RLS allows for co-location and brings the specialized expertise we need to bring PET diagnostics closer to hospitals and patients,” said Patrick Phelps, president & CEO of SOFIE, in a statement. According to SOFIE, RLS will provide it with last-mile delivery services, as well as significant space, exemplary regulatory status, and industry-leading clean rooms built to ISO 1644-1 specifications for compounding radiopharmaceuticals. RLS recently struck up a national group purchasing agreement with Premier where it will provide Premier’s members with compounding and delivery services at special pricing and pre-negotiated terms. It also partnered with SpectronRx , which will develop radiopharmaceuticals for it, using RLS’ radiopharmacy network to make them in bulk. RLS will then distribute them, with the aim being to address drug development, manufacturing and distribution issues in the supply chain process by enhancing production. RLS did not respond with comments in time for publication of this article.